[{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services | ACM Global Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services | ACM Global Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services | ACM Global Laboratories"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Encube Ethicals \/ CBCC Global","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ CBCC Global"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services"}]

Find Clinical Drug Pipeline Developments & Deals by Encube Ethicals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fluorouracil is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          October 15, 2021

                          Lead Product(s) : Fluorouracil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : CBCC Global

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 01, 2019

                          Lead Product(s) : Diclofenac Sodium

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 31, 2019

                          Lead Product(s) : Ketoconazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 07, 2017

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank